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A preferred strategy for preventing nerve agents
intoxication is catalytic scavenging by enzymes
that hydrolyze them before they reach their targets.
Using directed evolution, we simultaneously en-
hanced the activity of a previously described serum
paraoxonase 1 (PON1) variant for hydrolysis of the
toxic SP isomers of the most threatening G-type
nerve agents. The evolved variants show %340-fold
increased rates and catalytic efficiencies of 0.2-5 3
107 M1 min1. Our selection for prevention of
acetylcholinesterase inhibition also resulted in the
complete reversion of PON1’s stereospecificity,
from an enantiomeric ratio (E) < 6.3 3 104 in favor
of the RP isomer of a cyclosarin analog in wild-type
PON1, to E > 2,500 for the SP isomer in an evolved
variant. Given their ability to hydrolyze G-agents,
these evolved variants may serve as broad-range
G-agent prophylactics.
INTRODUCTION
G-type nerve agents—tabun (GA), sarin (GB), soman (GD) and
cyclosarin (GF; Figure 1A)—are highly toxic organophosphates
(OPs) that penetrate the body by both inhalation and skin
absorption (Romano et al., 2008). Following their entrance,
G-agents bind to and inhibit the enzyme acetylcholinesterase
(AChE), thus causing a cholinergic crisis that may result in respi-
ratory failure and death (Newmark, 2007). All G-agents possess
a chiral phosphorous center, and their optical isomers differ in
their toxicity. The Sp isomers of GB, GD, and GF inhibit acetyl-
cholinesterase (AChE) >1,000-fold faster than their respective
Rp isomers and can be >100-fold more toxic in vivo (Benschop
and Dejong, 1988). GD additionally contains a chiral carbon
center (Figure 1A) and is synthesized as a racemic mixture of
four optical isomers. However, only its two Sp isomers are
considered toxic: SpSc and SpRc (Benschop et al., 1984). In the
case of GA, nomenclature conventions ascribe an Rp configura-456 Chemistry & Biology 19, 456–466, April 20, 2012 ª2012 Elseviertion to its toxic isomer (Carletti et al., 2010). Current treatments
following OP intoxications are symptomatic and do not act to
intercept the OP before it reaches its target (Cannard, 2006;
Dunn and Sidell, 1989). A better treatment strategy would
employ OP hydrolyzing enzymes as prophylactic drugs that
would promote rapid OP degradation in vivo (Doctor and Sax-
ena, 2005; Lenz et al., 2007). Unfortunately, all OP-hydrolyzing
enzymes isolated thus far hydrolyze the toxic isomers of nerve
agents with low catalytic efficiencies (diTargiani et al., 2010;
Theriot and Grunden, 2011). Attempts to increase the activities
of OP-hydrolyzing enzymes have been reported (for recent
examples, see Hemmert et al., 2011; Tsai et al., 2010). However,
currently there are no available enzymes that can hydrolyze
the toxic isomers of nerve agents at sufficiently high rates to
confer effective prophylactic protection using low protein doses
(%50 mg/70 kg). PON1 is a mammalian lactonase that resides
in the liver and on HDL blood particles and plays a role in drug
metabolism and in the prevention of atherosclerosis (Draganov,
2010; Seo and Goldschmidt-Clermont, 2009). In addition, it
exhibits promiscuous OP-hydrolyzing activities (Harel et al.,
2004; Khersonsky and Tawfik, 2005). Human PON1, and the
other mammalian PONs, hydrolyse G-agents at low catalytic
efficiencies and react primarily with their less toxic Rp isomers
(Amitai et al., 2006). Previously, using directed evolution, we
obtained recombinant PON1 (rePON1) variants that efficiently
hydrolyze the toxic Sp isomer of GF (%1.75 3 10
7 M1 min1)
and demonstrated the in vivo prophylactic activity of such an
evolved variant in mice using a GF surrogate (Gupta et al.,
2011). The model we had developed, and our in vivo protection
experiments, indicate that the catalytic efficiency (in kcat/KM
terms) required for effective prophylactic protection using
minimal enzyme doses (%50 mg/70 kg) against 2 3 LD50 of
G-type agents should beR107 M1 min1 (Gupta et al., 2011).
Here, we report additional rounds of mutagenesis and
screening that improved the catalytic activities of our starting
variant by 3- to 340-fold and gave PON1 variants whose catalytic
efficiencies toward the toxic isomers of GD, GF, and GB are
up to 5 3 107 M1 min1, 3.4 3 107 M1 min1, and 3.2 3
106 M1 min1, respectively. The overall improvements in
catalytic activities of these variants relative to wild-type PON1
ranged from 40- to 3,400-fold. Although we did not screen theLtd All rights reserved
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Figure 1. Structures of the Nerve Agents and Their Analogs Used in
This Work
(A) Structures of GA, GB, GD, GF, and VX. Shown are the toxic isomers, that is,
the more potent AChE inhibiting isomers (SP, for GB, GD, GF, and VX; Rp for
GA). The chiral carbon of GD is indicated by an asterix.
(B) Structures of the Sp isomers of the coumarin analogs of GD (PMP-
coumarin) and GF (CMP-coumarin).
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isomer of GA with catalytic efficiencies of up to 2.3 3 106 M1
min1. A detailed characterization indicated that the dramatic
increase in PON1’s catalytic efficiency toward the toxic isomers
resulted in the complete reversal of its stereospecificity from Rp
to Sp preference. We also show that our evolved variants protect
human blood cholinesterases ex vivo from inhibition by GF for at
least 24 hr, thus supporting the possibility of utilizing them for
in vivo prophylaxis. Finally, we found that our evolved variants
had improved by >150-fold relative to wild-type PON1 for
hydrolysis of the toxic isomer of VX (Figure 1A), thus providing
a starting point for the directed evolution of PON1 for neutraliza-
tion of V-type agents.
RESULTS
The Starting Point
As a starting point for directed evolution toward GD and GB
hydrolysis, we used PON1 variants that were previously evolved
toward GF hydrolysis (Gupta et al., 2011). These were derived
from a recombinant variant of mammalian PON1, dubbed
rePON1-G3C9, that is expressed functional and soluble in
E. coli and exhibits enzymatic specificities that are essentially
identical to human PON1 (Aharoni et al., 2004). The catalytic
activities of the rePON1 variants that were evolved toward GF
were tested with GB and GD. We found several variants that
were similar in sequence and were improved relative to the
wild-type-like rePON1 by up to 135- and 37-fold with the twoChemistry & Biology 19,toxic isomers of GD and up to 4-fold with the toxic isomer of
GB (Table S1 available online). One of these variants, 2D8, which
carried the smallest number of mutations yet exhibited the
highest activity, was chosen as the starting point for further
evolution (Table 1).
Library Design and Screening
We generated gene libraries derived from 2D8 by structure-
guided targeted mutagenesis. This enabled us to generate
smaller and more focused libraries that could be screened by
our medium-throughput 96-well plate screen. Several strategies
were applied as detailed below.
Strategy 1: Targeted Diversification of Active-Site
Residues
An examination of the structures of unbound PON1 (Protein Data
Bank [PDB] code 1V04; Harel et al., 2004), PON1 in complex with
the inhibitor 2-hydroxyquinone (PDB code 3SRG; Ben-David
et al., 2012), and a docking model of PON1with the OP pesticide
paraoxon (Ben-David et al., 2012) indicated that active-site posi-
tions 70, 71, 196, 240, and 292 (Table 2) could affect OP binding
and catalysis. In addition we decided to explore positions 69,
115, and 134 of active-site residues that were substituted in
the earlier rounds of directed evolution toward GF hydrolysis.
We constructed a library of variants by spiking mutations in
these eight active-site positions into the 2D8 gene in a combina-
torial manner using the ISORmethod (Herman and Tawfik, 2007).
In general, residues were mutated to amino acids with similar
physicochemical properties, although more drastic changes
were also included (e.g., Gly69Leu/Val/Ile). Sequencing of
randomly selected clones revealed that the unselected library
contained on average 4 ± 1mutations per clone, with each clone
exhibiting a different mutational composition. This round 1 library
was then screened with in-situ-generated GD and GB, using the
AChE inhibition assay (Experimental Procedures). This assay
measures the ability of PON1 variants to protect AChE activity
by rapidly hydrolyzing the toxic isomer of the added OP.
By the end of Round 1, all improved variants had acquired
mutations at two positions, 69 and 115, which were previously
mutated to improve GF hydrolysis (Gupta et al., 2011). The
improved variants carried additional mutations, primarily at
positions 70, 71, 196, 240, or 292, but these varied from one
variant to another (Table S2).
The changes in residues 69 and 115 led us to explore the
re-optimization of another key active-site residue, 222, the
mutagenesis of which to Ser had led to increased GF hydrolysis
(Gupta et al., 2011). We therefore explored mutations of
Ser222 to hydrophobic residues (Leu, Val, Ile, Met, or Cys) in
the second round (Table 2). Indeed, 96% (24/25) of the improved
variant from round 2 were mutated in position 222, mostly to
Met (17/24).
Positions 69, 115, and 222 that were substituted in the first
two rounds reside at the bottom of PON1’s active-site and close
to the catalytic calcium. However, in the third round library, we
targeted residues whose side chains are involved in structuring
the top of PON1’s active-site cleft. These included positions
50, 197, 291, 294, 346, 347, and 348. In addition, we retargeted
positions 196 and 292 (Table 2). On average, variants in the
unselected third round library contained 2 ± 1 substitutions at
the targeted positions. Following screening with GB and GD,456–466, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 457
Table 1. Catalytic Activities of the Best Variant from Each Round
Variant
Mutations Relative
to rePON1a Round
Catalytic Efficiencyb (kcat/KM) 3 10
7 M1min1
GD Fastc GD Slowc GF GB GA
rePON1 – – 0.0055 ± 0.002 0.0015 ± 0.0006 0.013d ± 0.003 0.008 ± 0.001 0.043 ± 0.007
2D8 Leu69Gly, His115Trp,
His134Arg, Phe222Ser,
Thr332Ser
0 0.4 ± 0.1 0.015 ± 0.003 0.46d ± 0.01 0.025 ± 0.002 0.082 ± 0.005
Fold improvement
relative to (rePON1)e
(73) (10) (35) (3) (2)
PG11 Leu69Val, His115Ala,
His134Arg, Phe222Ser,
Thr332Ser
1 1.43 ± 0.3 0.32 ± 0.04 0.2 ± 0.03 0.02 ± 0.005 0.006 ± 0.001
Fold improvement
relative to variant
2D8 (rePON1)e
4 (260) 21 (213) 0.4 (15) 0.8 (3) 0.07(0.1)
VII-D11 Leu69Val, His115Ala,
His134Arg, Phe222Met,
Asp309Gly, Thr332Ser
2 2.9 ± 0.9 2.9 ± 0.1 1.07 ± 0.08 0.12 ± 0.01 0.025 ± 0.003
Fold improvement
relative to variant
2D8 (rePON1)e
7(527) 193(1933) 2(82) 5(15) 0.3(0.6)
1-I-F11 Leu55Met, Leu69Val,
His115Ala, His134Arg,
Phe222Met, Ile291Leu,
Thr322Ser
3 4.4 ± 0.6 4.4 ± 0.6 1.52 ± 0.1 0.39 ± 0.04 0.17 ± 0.04
Fold improvement
relative to variant
2D8 (rePON1)e
11(800) 293(2933) 3(117) 16(49) 2(4)
IIG1f Leu55Ile, Leu69Val,
His115Ala, His134Arg,
Asp136Gln, Phe222Met,
Ile291Leu, Thr332Ser
4 5.1 ± 0.6 5.1 ± 0.6 3.4 ± 0.3 0.32 ± 0.01 0.23 ± 0.004
Fold improvement
relative to variant
2D8 (rePON1)e
13(927) 340(3400) 7(262) 13(40) 3(5)
aMutations relative to the wild-type-like rePON1 variant G3C9 (Harel et al., 2004). Mutations that were newly introduced in a given round are denoted
in bold.
bKinetic parameters relate to the toxic Sp isomers of GB, GD and GF or to the toxic Rp isomer of GA. Error ranges were derived from at least two
independent measurements. The maximal deviation between different enzyme preparations was%2-fold.
cFast and slow hydrolysis of the two equally toxic isomers of GD (ScSp and RcSp).
dValues from (Gupta et al., 2011).
eFold improvement in catalytic efficiencies relative to the starting variant 2D8 or relative to wild-type-like rePON1 (numbers in brackets). PG11, best
variant of round 1; VII-D11, best variant of round 2; 1-I-F11, best variant of round 3; IIG1, best variant of round 4.
fSee also Figure S5.
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291 were primarily mutated (in 4/18 and 8/18 of the improved
variants, respectively). Some positions did not accept any
mutations (196, 294, 346, 347, and 348), and others were
mutated in single clones (50 and 292).
Strategy 2: Shuffling of Improved Variants
Shuffling of selected variants can combine beneficial mutations
that were acquired in separate variants and/or eliminate delete-
rious mutations from individual variants. In particular, since
the theoretical mutational diversity in our libraries was large
compared to the number of clones screened (0.04% to 7% of
the theoretical library diversity), the improved variants generally
exhibited different mutational compositions (e.g., round three
in which little convergence was seen). In effect, shuffling of458 Chemistry & Biology 19, 456–466, April 20, 2012 ª2012 Elsevierimproved variants was applied in every round as part of the
ISOR protocol (Herman and Tawfik, 2007) that was used to
introduce the library mutations. However, for the round 4 library,
shuffling was applied with no spiking of targeted mutations
(Table 2).
Strategy 3: Targeted Mutagenesis of the Flexible
Active-Site Loop
PON1’s longest active-site loop (residues 70–78) is highly flexible
and disordered in the crystal structures of unbound PON1
(Harel et al., 2004). Upon binding of the lactam inhibitor 2-
hydroxyquinoline (2HQ), the loop became structured and
thereby completed the active site (Ben-David et al., 2012). There-
fore, we designed a second round 3 library that explored active-
site loop mutations. Given the very small size of the fluorideLtd All rights reserved
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introduced large side chains, such as Trp, Phe, and Tyr, which
could reduce the active site’s volume and improve substrate
binding. We also attempted to modulate the loop’s configuration
by exploring mutations to Gly and Pro (Table 2). Each clone in
the unselected library carried, on average, one loop mutation.
Strategy 4: Ancestral Mutations
Ancestral mutations, that is, substitutions into residues that
appeared along the evolutionary history of a given protein,
have been shown to be powerful modulators of a protein’s
stability and function (Bershtein et al., 2008; Chen et al., 2010).
A library based on active-site substitutions from the predicted
ancestors of mammalian PONs has been described (Alcolombri
et al., 2011). Screening this library with a coumarin analog of
GF (CMP-coumarin; Figure 1B) led to the identification of several
ancestral mutations that increase this activity (Alcolombri
et al., 2011). We included these mutations (Leu55Ile, Ile74Leu,
Asp136His, and Pro189Gly) together with similar ones (55Met/
Val, 136Gln, and 189Ser) in the round 3 substitution library
at an average frequency of 0.5 mutations per gene in the
unselected library (Table 2).
Directed Evolution of rePON1 for G-Agent Hydrolysis
Table 1 summarizes the results of four rounds of directed evolu-
tion starting from variant 2D8 and screening for GB and GD
hydrolysis. After screening 2,000 variants in round 1, we iden-
tified 21 clones that in crude cell lysates were improved up to
4-fold with GB and up to 5-fold with GD relative to the starting
point 2D8 (Table S2). The two most active variants with GD,
5H8 and PG11, were purified and characterized (Tables 1 and
S1). We found an improvement of 21- and 4-fold in the catalytic
activity of the best variant PG11 with the two toxic isomers of GD
relative to the starting variant 2D8 (Table 1). However, PG11’s
activity with GF was reduced 2.3-fold, and its GB activity was
the same as 2D8’s. The best two variants shared the same
four active-site mutations—Leu69Val, His134Arg, Phe222Ser,
and Thr332Ser—but differed in position 115.
For the second round, we constructed a substitution library
that explored various substitutions at position 222 while shuffling
the ten most active clones found in round 1 (Table S3). The
resulting library was screened for GD and GB, as well as GF.
The latter was included to eliminate variants that exhibit reduced
activity with GF as observed with variants isolated from the first
round. Of the 1,000 clones screened, we isolated 39 improved
variants, 25 of which were unique (Table S4). Following addi-
tional screens, we identified the six most active variants, purified
them, and characterized them. The purified variants exhibited
up to 7- and 193-fold higher specific activities with the two toxic
isomers of GD and up to 5-fold higher activities with GB, relative
to the starting variant 2D8 (Tables 1 and S1). Their activities with
GF became similar to that of 2D8, and all but one contained
a Phe222Met mutation (Tables 1 and S1). Though no attempt
was made to introduce random mutations during library con-
struction, the polymerase chain reaction (PCR) methodologies
applied for library making, produced random mutations, such
as Phe64Leu or Asp309Gly, which were retained in certain
improved variants. By round 2, the most improved variants
reached the targeted catalytic efficiency of R107 M1 min1
with GD and GF but were still 10-fold lower in activity with GB.Chemistry & Biology 19,The best round 2 variant, VII-D11, hydrolyzed the two toxic
isomers of GD with equally high rates (2.9 3 107 M1 min1;
Table 1).
In the third round, two libraries were constructed, and 400 vari-
ants from each library were screened with GD and GB (Tables 2
and S5). We identified 18 improved clones altogether. All these
clones were improved with GB, but only 67% (12/18) were also
improvedwith GD (Table S6). Most of the improved variants orig-
inated from library #3.1 (73%, 13/18), and their improvements
with GB (1.6- to 4-fold) were greater than with GD (1.1- to 1.6-
fold). Sequencing indicated that 55% (10/18) of these improved
variants contained at least one ancestral mutation (Leu55Ile or
Asp136His), and 28% (5/18) contained two ancestral mutations.
In addition, the active-site mutation Ile291Leu became abundant
(39%, 7/18). Certain mutations introduced in earlier rounds,
His134Arg and Phe222Met, were fixed (i.e., appeared in all
improved variants) and others, Leu69Val and His115Ala, were
nearly fixed (90%, 16/18; Table S6).
We purified and characterized the four most improved variants
of round 3. Relative to 2D8, their catalytic efficiencies were
improved up to 11- and 293-fold with the two toxic isomers of
GD and up to 17-fold with GB (Tables 1 and S1). Although 2D8
was evolved for GF, a further %3-fold improvement with GF
was identified in round 3 variants. The catalytic efficiency of
our most improved variant with GB (1-I-F11, 3.9 3 106 M1
min1) was improved >3-fold relative to the best round 2 variant
but was still 2.5-fold lower than our goal.
In round 4 (Tables 2 and S7), 700 clones were screened with
GB and GD, and 22 improved variants were isolated, of which
18 were singular (Table S8). Of these, 66% (12/18) were
improved mostly with GB, and 33% (6/18) were improved also
with GD. In addition to the mutations fixed in earlier rounds,
His115Ala was fixed, and most variants also carried Leu55Ile
(55%, 10/18) and/or Ile291Leu (83%, 15/18; Table S8). We puri-
fied nine variants and identified three variants that had improved
relative to the starting variant 2D8 by%13- and 340-fold with the
toxic isomers of GD, %7-fold with GB, and %9-fold with GF
(Tables 1 and S1). Although their catalytic efficiencies with GB
(1.7-3.2 3 106 M1min1) were 3- to 6-fold lower than our
desired goal, their catalytic efficiencies with GF and GD were
well over 107 M1 min1 (Tables 1 and S1; Figure 2).
Neutralization of GA
The in vivo toxicity of GA is >2-fold lower than that of all other
G-agents (Benschop and Dejong, 1988), thus ranking it as the
least toxic of the G-agents. In addition, its structure and leaving
group are significantly different than that of all other G-agents
(Figure 1A), suggesting that variants improved at hydrolyzing
the three other G-agents might exhibit lower rates with GA
and vice versa. Thus, we did not screen our libraries for GA
neutralization. Instead, we examined the activity of wild-type
like rePON1 and of the most improved variants from the four
rounds of evolution described here with GA. Using the AChE
inhibition assay, we found that rePON1 is %40-fold more effi-
cient at hydrolyzing the toxic isomer of GA than the toxic
isomers of all other G-agents (Table 1). The most improved vari-
ants from rounds 3 and 4 became 4- to 5-fold more efficient
than rePON1 at hydrolyzing the toxic isomer of GA (1-I-F11
and IIG1; Table 1). Thus, although GA neutralization was not456–466, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 459
Table 2. Summary of Directed Evolution Rounds
Round
Mutagenesis
Strategy Spiked Mutationsa Shuffling
Screening/
Substrate
Fold Improvement Measured
in Crude Cell Lysates
1 1 Gly69Leu/Val/Ile/Ser – 2,000 clones
screened
with GB,GD
21 improved variantsb.%4-fold
with GB and%5-fold with GD
relative to the starting point
(2D8). Best variant: PG11
Lys70Ala/Ser/Gln/Asn
Tyr71Phe/Cyc/Ala/Leu/Ile
Trp115Leu/Cyc/Gly/Ala/Val
Arg134His/Gln/Asn
Met196Leu/Ile/Phe
Leu240Ile/Val
Phe292Ser/Val/Leu
2 1 Ser222Leu/Val/Ile/Met/Cys 10 best
clones from
round 1c
1,000 clones
screened with
GB, GD, and GF
25 improved variantsd.
%4-fold with GB,% 2-fold
with GD and%4 fold
with GF relative to PG11.
Best variant: VIID11.
3 1 Library 3.1 7 best
clones from
round 2e
400 clones
from library 3.1
screened with
GB and GD
18 improved variantsf.%4 fold
with GB,%1.6-fold with GD
relative to VIID11. Best variant:
1-I-F11
Asn50Gly/Ala
Met196Phe/Ile
His197Lys/Ser/Arg/Gln/Asn/Thr
Ile291Phe/Trp/Leu
Phe292Leu/Ile/Trp
Tyr294Phe/Gln/Asn
Val346Leu/Ile/Phe/Trp
Phe347Gly/Ala/Ile/Leu/Val/Thr
/Ser/Trp
His348Gly/Ala/Ile/Leu/Val/Thr
/Ser/Trp
3 4 Library 3.1:
Leu55Ile/Met/Val
Ile74Leu
Asp136His/Gln
Pro189Gly/ Ser
3 3 Library 3.2: 7 best
clones from
round 2e
400 clones
from library 3.2
screened with
GB and GD
Gly69Met/Ala
Lys70Ser/Gln/Thr/Glu/Asp/Arg
Tyr71Phe/Trp/Met/Cyc
Pro72Gly/Ser
Gly73Pro/Ser
Ile74Trp/Phe/Pro/Ser/Gly
Met75Leu/Trp/Phe/Pro
Phe77Gly/Ala/Ile/Leu/Val/Thr/
Ser/Trp/Ile/Leu/Met
Asp78/Asn/Gln/Ser/Ala/Val/
Tyr/Gly/Ser/Pro
4 2 No mutations spiked 18 best
variants from
round 3g
libraries 3.1
and 3.2
700 clones
screened with
GB and GD
18 improved variantsh.%2 fold
with GB,%2-fold with GD relative
to 1-I-F11. Best variant: IIG1
See also Figure S4.
aThe average frequency of random mutations in unselected library clones was 0.5 ± 0.3.
bSee Table S2.
cSee Table S3.
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Figure 2. Hydrolysis of GD by Evolved Variants
Residual AChE activity was assayed and plotted as % inhibition of AChE
after the incubation of in situ generated GD with variants as follows: 2D8 and
VIID11 (100 nM, GD), IIG1 (80 nM, GD), and rePON1 (50 nM, GD). Variant
concentrations are noted in the figure. Data were fitted to a biphasic rate
equation to derive the apparent rate constants for hydrolysis of the two toxic
isomers of GD.
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with GA had increased and became similar to that with GB
(3 3 106 M1 min1).
Stereospecificity of the Evolved Variants
Library screening and variant characterization were done using
racemic G-agent solutions. However, the AChE assay we em-
ployed can only detect the hydrolysis of the toxic isomers of
G-agents (Sp for GB, GD, and GF and assuming Rp for GA). To
examine the hydrolysis of both stereoisomers, we assayed the
most improved variants from each round of directed evolution
with the purified Rp and Sp isomers of the coumarin analogs of
GF and GD (CMP-coumarin, PMP-coumarin; Figure 1B). The
activities of OP-hydrolyzing enzymes with coumarin analogs
and with the G-type nerve agents themselves appear to be
well correlated, not only for our engineered PON1 variants
(Gupta et al., 2011) but also for other OP-hydrolyzing enzymes
(Tsai et al., 2010). Our results indicated that the evolution of
higher detoxification rates of the three target G-agents (GB,
GD, and GF) was accompanied by a complete reversion in
rePON1’s stereoselectivity (Table 3). The catalytic efficiency
(kcat/KM) of the wild-type-like rePON1 with Rp-CMP-coumain
is >1,600-fold higher than with Sp-CMP-coumarin. In contrast,
the kcat/KM value of the best variant from round 3 (1-I-F11) with
Sp-CMP-coumarin is >2,500-fold higher than with Rp-CMP-
coumarin (Table 3; Figure S1).dSee Table S4.
eSee Table S5.
fSee Table S6.
gSee Table S7.
hSee Table S8.
Chemistry & Biology 19,The increase in Sp/Rp stereoselectivity with CMP-coumarin
was attributed to a decrease in the KM value for Sp-CMP-
coumarin and a concomitant increase in kcat. Parallel increases
in KM and decreases in kcat values were observed with Rp-
CMP-coumarin (Table 3).
A similar trend was observed with the coumarin analog of
GD, PMP-coumarin (Figure 3). While the best round 1 variant
hydrolyzed all four diasteroisomers of PMP-coumarin at measur-
able rates, variants from rounds 2 to 4 hydrolyzed only 50% of
the racemic mixture (Figure 3A). To confirm that the hydrolyzed
fraction corresponds to the Sp isomer pair, we applied the
evolved rePON1 variant 3B3 that hydrolyzes almost exclusively
the Rp isomers of coumarin G-agent analogs (Ashani et al.,
2010). Indeed, following the action of 3B3 that hydrolyzed 50%
of a racemic mixture of PMP-coumarin, the remaining 50%
were readily hydrolyzed by evolved variants from rounds 2–4
(Figure 3B).
To examine the stereopreference of variants toward GA, we
compared the hydrolysis rates obtained by the AChE assay
that detects only the hydrolysis of the toxic isomer of GA
(Table 1), to 31P-nuclear magnetic resonance (NMR) kinetics
thatmonitored the hydrolysis of bothGAenantiomers (FigureS2).
The results indicated that wild-type-like rePON1 and variant
2D8 hydrolyze the toxic Rp isomer of GA with similar efficiencies,
4.3 3 105 and 8.2 3 105 M1 min1, respectively, whereas
variant VIID2 had improved with the toxic Rp isomer (1.83 3
106 M1 min1).
Activity and Stability in Human Blood Samples
The use of evolved PON1 variants as prophylactic drugs
depends on their ability to maintain activity in human blood
over long periods of time. Previously, we showed that evolved
variants 4E9 and VIID2 protect human blood cholinesterases
(ChE) from inhibition by GF in an ex vivo assay (Ashani et al.,
2011). Whereas this assay does not necessarily reflect their
in vivo bioavailability, it comprises a facile way of assessing
the stability and activity of the evolved PON1 variants in the
blood. Variants PG11, VIID11, 1-I-F11, and VIID2 (from rounds
1–4, respectively) were added to human blood samples and
incubated at 37C. In-situ-generated GF was added at different
time intervals, and the residual blood ChE activity wasmeasured
(Figure 4A). Becauase of its low catalytic efficiency, round 1
variant PG11 could not provide measurable ChE protection at
the concentration range used (0.5–2.1 mM). However, variants
VIID11, 1-I-F11, and VIID2 showed measurable ChE protection
(41%–45%) after 5 min of incubation. Further, these variants
maintained 80%95% of their initial protection activity in human
blood after 24 hr of incubation at 37C (Figure 4A). The rate of
CMP-coumarin hydrolysis at different time intervals following
incubation in whole blood (Figure 4B) or buffer (Figure S3) also
gave very similar results. Taken together, these results suggest
that the interaction of the evolved PON1 variants with human456–466, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 461
Table 3. Stereoselectivity with Sp- and Rp-CMP-Coumarin
Round No. Variant
SP-CMP-Coumarin RP-CMP-Coumarin
E (Sp/Rp)
a
kcat
(min1)
KM
(mM)
kcat/ KM
(mM1 min1)
kcat
(min1)
KM
(mM)
kcat/ KM
(mM1 min1)
– rePON1
wild-type-likeb
ndc ndc <0.0002 14.5 (±0.5) 45 (±6) 0.322 <0.0006
1 PG11 632 (±5) 104 (±12) 6.1 106 (±2.5) 437 (±34) 0.243 25
2 VIID11 500 (±19) 105 (±1) 4.8 107.5 (±4) 1,307 (±155) 0.082 59
3 1-I-F11 1004 (±98) 83 (±4) 12.1 ndc ndc 0.0047 2,575
4 VIID2d 1188 (±24) 79 (±2) 15 25.5 (±1.3) 2,658 (±419) 0.0096 1,563
See also Figures S1A and S1B.
aThe enantiomeric ratio is the ratio of catalytic activity (kcat/KM) with Sp-CMP-coumarin to the catalytic activity (kcat/KM) with Rp-CMP-coumarin.
bValues for rePON1 (G3C9) with Sp-CMP coumarin are from (Gupta et al., 2011). Values with Rp-CMP-coumarin update previous ones from (Gupta
et al., 2011) that were obtained with racemic-CMP-coumarin, using a purified Rp- substrate containing%2% Sp-CMP-coumarin.
cnd, not detectable.
dSee Table S1.
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24 hr at 37C.
Neutralization of VX
Chemical warfare nerve agents are generally divided into G- and
V-agents (Romano et al., 2008). Whereas most G-agents have
a small and highly reactive fluoride leaving group (pKa = 3.1),
V-type agents have a bulky and far less reactive N,N-dialkylami-
noethylthiolate leaving group (pKa = 7.9) (Bracha and O’Brien,
1968; Figure 1A). V-agents pose a greater threat due to their
increased toxicity, persistency, and skin penetration and as
such are prime targets for detoxification. However, the hydro-
lysis of the toxic Sp isomer of VX by wild-type-like rePON1,
and by human PON1 (unpublished data), is below the detection
limits <2 M1 min1. We found that the previously described
GF-detoxifying variants (Gupta et al., 2011) exhibit higher effi-Figure 3. Hydrolysis of PMP-Coumarin by Evolved Variants
(A) The hydrolysis of a racemic mixture of PMP-coumarin (10 mM) by various PON1
was observed upon addition of NaF (0.25 M). Partial hydrolysis, restricted to Rp is
3B3 (Ashani et al., 2010).
(B) The hydrolysis of Sp PMP-coumarin isomers (SpRc,SpSc) by evolved variants
(indicated by a dashed arrow), samples were pre-incubated with the Rp specific
462 Chemistry & Biology 19, 456–466, April 20, 2012 ª2012 Elsevierciencies with VX, e.g., 80 M1 min1 for 4E9 and 93 M1 min1
for 8C8. Round 4 variants evolved for hydrolyzing GB, GD, and
GF were further improved; the catalytic efficiencies of variants
VIID2 and VH3 with Sp-VX are 132 and 286 M
1 min1, respec-
tively. Thus, although these variants were evolved for broad-
range G-agent hydrolysis, they also exhibit >100-fold higher
rates than wild-type PON1 for VX neutralization.
DISCUSSION
Our long-term goal is to obtain variants that efficiently detoxify
the entire spectrum of G-type nerve agents in vivo. Based on
our previously evolved variants for GF detoxification (Gupta
et al., 2011), we aimed to increase the hydrolytic activity of
PON1 toward the toxic isomers of the threemost toxic G-agents,
GB (sarin), GD (soman), and GF (cyclosarin), to obtainvariants (0.5 mM) wasmonitored at 400 nm. Complete hydrolysis of all isomers
omers (RpSc, RpRc), was displayed by the previously described rePON1 variant
was monitored under similar conditions. Prior to the addition of these variants
variant 3B3. Complete hydrolysis was monitored by addition of NaF.
Ltd All rights reserved
Figure 4. Activity in Blood Samples
Error bars represent the standard deviation derived from three independent
experiments.
(A) Protection by evolved variants of blood cholinesterases from inhibition by
GF. Evolved variants (0.5–2.1 mM) were incubated in whole blood samples
(37C) for 24 hr. GF was added (0.1 mM) and the samples were assayed for
residual AChE activity. Cholinesterase protection activity was compared to the
initial protection levels observed after 5 min of incubation (41%–45%).
(B) Hydrolytic activity in whole blood samples. Evolved variants (0.3–1.1 mM)
were incubated in whole blood samples (37C) for 24 hr. Incubated samples
were diluted in buffer and residual enzyme activities were assayed with CMP-
coumarin. The percent activity was determined relative to the hydrolytic
activity observed after 5 min incubation.
See also Figure S3.
Chemistry & Biology
Evolution of Broad-Spectrum G-Agent Hydrolasescatalytic efficiency (kcat/KM) values that areR10
7 M1 min1. By
selecting variants that exhibit high rates with all three agents, we
were able to improve catalytic efficiency while maintaining rela-
tively broad substrate specificity.
Libraries were generated by diversifying the active-site resi-
dues of the previously evolved GF-hydrolyzing variant 2D8.
The selection pressure was applied gradually by increasing
the concentration of the applied G-agents and screening for
both GB and GD, as well as GF in one round. The largestChemistry & Biology 19,improvements were obtained with GD. Owing to the similarity
in size and hydrophobicity of their alkyl moieties, the increase
in catalytic efficiency toward GD resulted in maintaining or
even increasing the activity with GF. However, the improvements
in catalytic activity with GB were far more limited. It seems that
efficient hydrolysis of GB that contains a smaller moiety
(O-isopropyl) trades off with efficient hydrolysis of GD and GF
that carry bulkier O-alkyl groups. Indeed, variants like 5H8,
PG11, and VIID2 had improved relative to variants of the
previous round with GD or GF at the expense of a reduction in
their GB activity (Tables 1 and S1). On the other hand, variants
like 2-II-D12 and 1-I-D10 had improved with GB at the expense
of their GD or GF activities (Table S1). Thus, beyond a certain
threshold of catalytic efficiency, higher catalytic efficiency with
the smaller substrate comes at the expense of the bulkier
ones. This trend is in accordance with the notion that broad
specificity trades off with catalytic efficiency, and that evolu-
tionary ‘‘generalists’’ are less fit than ‘‘specialists’’ in their envi-
ronments (Straub et al., 2011).
GA fundamentally differs from the three other G-agents in its
chemistry (Figure 1A) and its lower in vivo toxicity (Benschop
and Dejong, 1988). For these reasons, we did not screen our
libraries for GA neutralization. Nonetheless, the evolved variants
from rounds 3 and 4 show mild improvements in GA hydrolysis
(%5-fold relative to wild-type-like rePON1). Overall, the activity
of improved variants with GA and with GB are 5-fold lower
than our desired goal (Table 1), However, considering GA’s
and GB’s relatively low inhibition constants of AChE (10- to
121-fold lower than that of GD and GF; Benschop and Dejong,
1988; Blum et al., 2008), the catalytic efficiency of round 4 vari-
ants might be sufficient to provide effective prophylactic protec-
tion against all four G-agents.
Broad specificity and overall improvements in catalytic effi-
ciency were achieved through mutations in positions that are,
to our knowledge, new, as well as by the replacement of posi-
tions that were already mutated in 2D8 and in other GF evolved
variants (Gupta et al., 2011). The re-optimized positions, 69, 115,
and 222, had all been shown to increase the activity of PON1with
other OPs (Amitai et al., 2006; Gupta et al., 2011), and their
replacement seems to be the key to PON1’s ‘‘activity matura-
tion’’ toward various nerve agents. Position 115 is close to
PON1’s catalytic calcium and mutations in this position trigger
a change in PON1’s catalytic chemistry. Mutating His115, that
takes part in activating the nucleophilic water for lactone hydro-
lysis, converts PON1 from a lactonase with promiscuous OP
hydrolase activity into an OP hydrolase with almost no lactonase
activity (Ben-David et al., 2012; Khersonsky and Tawfik, 2006).
Position 69 is in contact with 115 and also comprises part of
the active-site wall (Harel et al., 2004). Mutations in these two
positions seem to be correlated. Under selection for improved
GF hydrolysis, the mutation His115Trp was followed by
Leu69Gly. The subsequent selection of a G-generalist led to
the exchange of Gly69Val in the first round, and of Trp115Ala
in the third round (Tables S2 and S6). Concomitant changes in
position 222 that faces the opposite side of the catalytic calcium
were observed. The mutation Phe222Ser was fixed under selec-
tion for GF, and this residue changed again (Ser222Met) under
selection for a G-generalist. It therefore seems that PON1’s
OPH activity is mostly shaped by these three positions.456–466, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 463
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Thr332Ser mutation appears to be a global suppressor that
accompanies nearly all specificity changes in PON1. The muta-
tion Ile291Leu, in combination with Ser222Met, seems to
contribute to the dramatic shift in stereospecificity (e.g., variant
1-I-F11 vs. PG11 Table 3). Leu55Ile (an ancestral mutation in
a buried position) probably compensates for the destabilizing
effects of active-site mutations, as observed for other ancestral
substitutions (Bershtein et al., 2008). Finally, mutations at posi-
tions, such as 134 and 136, comprise second-shell mutations
because these positions are in contact with mutated active-
site positions (e.g., 134 contacts 115).
In addition to highly improved rates, we also observed
a dramatic shift in stereoselectivity. This shift is manifested in
the enantiomeric ratio of variants with the coumarin analog of
GF (Table 3; Figure S1). The E value (ratio of kcat/KM values)
shifted from >1,600-fold in favor of the RP isomer in wild-type-
like rePON1 to >2,500-fold in favor of the SP isomer of CMP-
coumarin in evolved variant 1-I-F11 (Table 3). To our knowledge,
a shift in enantiomeric ratio of >106-fold has not been reported,
not even in enzymes that were explicitly evolved for reversal of
stereoselectivity (Bartsch et al., 2008; Boersma et al., 2008;
Reetz et al., 2001). The screen for protection of AChE led to
enzymes that exclusively target the SP isomers of the applied
G-agents. Since the nerve agents are synthesized as racemates,
their RP isomers were also present during screening. However,
we observed no inhibition of the SP-CMP-coumarin hydrolyzing
activity of the evolved variants by the RP isomer of CMP-
coumarin. Further, the greatest change in stereospecificity
occurred in round 3 and was driven by a mild increase (2- to
3-fold) in the rate of hydrolysis of the SP isomer and a far larger
decrease in the rate of hydrolysis of the RP isomer (%52-fold;
Table 3). Thus, unlike cases where screening aimed for improved
enantioselctivity (Reetz et al., 2009) or even for both higher rates
and improved enantioselctivity (Reetz et al., 2010), the drop we
observed in hydrolysis rates of the RP isomer seem to have
resulted from the emergence of highly effective SP hydrolysis
(trade-off) and not because of explicit selection for enantioselec-
tivity (for a recent review, see Reetz, 2011).
The stereospecificity of evolved variants also changed with
respect to the two toxic carbon isomers of GD (SpRc and
SpSc). In the starting point variant 2D8 and in variants of round
1, we detected two phases of hydrolysis with up to 30-fold
difference in rate for the two Sp-isomers of GD (Tables 1 and
S1). This difference disappeared by the end of round 3 as
exemplified by variant VIID11 (Figure 2; Table 1). Accordingly,
all variants of round 4 exhibited the same rates of hydrolysis of
the SpRc and SpSc isomers. The dramatic gain of stereospeci-
ficity toward the toxic SP isomers, and the loss of specificity
with respect to the Sc/Rc GD isomers are both a direct outcome
of screening for AChE protection. This screen was designed to
reproduce the challenge facing a detoxifying enzyme in vivo,
which is to neutralize the nerve agent before it inhibits AChE.
The resulting stereselectivities demonstrate the established
concept that ‘‘you get what you select for’’ (Romero and Arnold,
2009).
What our in vitro screen does not address is the need for the
detoxifying enzyme to be active in human blood and to remain
so for extended periods of time. Assuming the administration464 Chemistry & Biology 19, 456–466, April 20, 2012 ª2012 Elsevierof a single enzyme dose, the rate of its inactivation and clearance
will be mostly determined by processing in organs, such as the
liver and kidneys (Katsila et al., 2011; Lin, 2009), by blood
components that may inhibit the enzyme, by the overall stability
of the enzyme in the blood, and specifically by its susceptibility
to proteases in the blood (Patel et al., 2009). The only way to
evaluate the combined effect of all these factors is by measuring
the residence time of the administered enzyme in vivo. However,
this approach is not applicable for screening a large number of
variants. We therefore developed a preliminary screen that
examines the activity of the PON1 variants in human blood
ex vivo (Ashani et al., 2011). According to this preliminary test,
the broad spectrum variants described here appear to maintain
ChE protection in blood at levels that are comparable to buffer,
and maintainR75% activity for at least 24 hr at 37C.
Finally, the dramatic improvement of evolved variants with
G-agents prompted us to examine their ability to hydrolyze VX.
In contrast to wild-type PON1, the evolved variants described
here show measurable rates (kcat/KM values of 132 to 286 M
1
min1) with the toxic isomer of VX. Most crucially, this activity
is sufficiently high to be assayed for VX neutralization using
crude bacterial lysates, thus opening the road for screening
libraries and for evolving PON1 toward efficient V-agent
hydrolysis.
SIGNIFICANCE
We describe the enzyme variants that hydrolyze the toxic
isomers of G-type nerve agents with sufficiently high rates
to detoxify these agents in vivo, such that prophylactic
protection could be potentially achieved upon administering
low enzyme doses. Following only four rounds of directed
evolution, we obtained variants that were improved up to
340-fold relative to our previously described GF-hydrolyzing
variant. Overall, these variants show 40- to 3,400-fold higher
catalytic efficiencies than wild-type PON1 for hydrolyzing
the toxic isomers of the three most toxic G-agents (GB,
GD, and GF). Their kcat/KM values for GD and GF neutraliza-
tion are particularly high: 3-53 107M–1min–1. Although lower
by about an order of magnitude, their catalytic efficiencies
with GA and GB may still enable effective prophylaxis
because of the lower toxicity of these agents. This work,
therefore, demonstrates that, despite tradeoffs between
different substrates, catalytically efficient broad-spectrum,
generalist enzymes can evolve. Although the evolved vari-
ants show relatively broad specificity with respect to the
substrate’s O-alkyl group, their stereospecificity is remark-
ably high. Screening for variants that hydrolyze the toxic Sp
isomers resulted in possibly the highest recorded shift in
enantiomeric preference between the wild-type enzyme
and its evolved variants (Eevolved/Ewild-type > 106). Overall,
this work describes promising candidates for in vivo tests
of prophylaxis and postexposure treatment and a general
scheme for the evolution of highly active OP hydrolyzing
enzymes that could detoxify a broad range of nerve agents
and pesticides. It demonstrates the powers of laboratory
evolution and its ability to completely reshape the catalytic
activity and substrate specificity, as well as the stereoselec-
tivity of enzymes.Ltd All rights reserved
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Gene Libraries
Recombinant PON1 variants cloned into a pET vector with a C-terminal 6-His
tag (Gupta et al., 2011) were used as the template for library construction
using synthetic oligonucleotides and the ISOR protocol (Herman and Tawfik,
2007). Briefly, the genes of PON1 variants were PCR amplified, treated with
DpnI (NEB) and purified. Purified DNA (20 mg in 150 ml) was digested with
0.3 U DNaseI (Takara, Tokyo, Japan) at 37C for 0.5, 1, 1.5 and 2 min. The
reactions were terminated with 16 ml of 0.5 M ethylenediaminetetraacetic
acid (EDTA), inactivated at 80C for 15 min, and run on 2% agarose gel.
Fragments of 50–150 bps size were excised and purified by a gel extraction
(Qiagen, Venlo, The Netherlands). The intact gene was reassembled by PCR
from the DNA fragments (100 ng) with the addition of synthetic oligonucleo-
tides (1-10 nM; Table S9). The assembly product was amplified by nested
PCR using primers pET-Nes1-Bc and pET-Nes0-Fo (Gupta et al., 2011), puri-
fied, digested, (NcoI, NotI), and recloned into the pET32 vector.
Screening
BL21/DE3 cells expressing PON1 variants were plated on LB-agar plates (plus
100mg/l ampicillin and 1%glucose) and grownO/N at 37C. Randomly picked
colonies were individually grown in 96-deep-wells plates (500 ml 2YT per well,
plus ampicillin and CaCl2 1mM) for 24 hr at R.T. Cells were pelleted, frozen
(80C, 20 min), resuspended (200 ml, 0.1M Tris-HCl [pH 8.0], 1mM CaCl2,
10 mg/ml lysozyme, 0.2% Triton X-100, and 5 units/ml benzonase; Novagen,
Madison, WI, USA), lysed (1300 rpm, 45 min, 37C) and centrifuged
(4000 rpm, 20 min, 4C). Clarified cell lysates (40 ml) were mixed with an
AChE solution (40 ml, 1nM reAChE [Gupta et al., 2011], in phosphate buffered
saline [PBS], 0.1% BSA) in 96 well plates using an automated liquid-handling
system (Precision 2000, BioTek, Winooski, VT, USA). In situ generated
G-agents (Gupta et al., 2011; 20 ml, 0.1–1.5 mM) were added. Following
30 min incubation, reaction samples (20 ml) were mixed with the AChE
substrate and DTNB (180 ml, 0.85 mM DTNB, and 0.55 mM acetylthiocholine
in PBS) and initial rates were measured at 412 nm. The percentage of residual
AChE activity was determined.
Enzymes Purification
Cultures of BL21/DE3 plasmid transformed cells were grown (OD600nm = 0.5,
37C), induced (IPTG 1 mM, 4 h), harvested, resuspended, and disrupted by
sonication. Ammonium sulfate was added (55% w/v). The precipitate was
dissolved and dialyzed against activity buffer (Tris-HCl 50 mM [pH 8], CaCl2
1mM, NaCl 50mM, and Tergitol 0.1%) and purified on Ni-NTA (Novagen).
Fractions were analyzed for purity (by SDS-PAGE), pooled, dialyzed against
activity buffer supplemented with 0.02% sodium azide, and stored at 4C.
Protein purity was typically 70%–85% by SDS-PAGE gel.
Determination of kcat/KM by AChE Inhibition
In situ generated agents (40 nM; Gupta et al., 2011) were mixed with purified
PON1 variants (10-0.01 mM) in activity buffer. Reaction mixture samples
were diluted (1:10) into an AChE solution (4 nM TcAChE, 0.1% BSA, and
1 mM EDTA in PBS), incubated 15 min), and their residual AChE activity was
determined as described above. The %-inhibition of AChE by the G-agent
without preincubation with a PON variant was considered as 100% inhibition.
Normalized%-inhibition values were calculated, and the apparent kcat/KMwas
derived from the slope of the resulting single exponential curve.
Determination of kcat/KM Values with Sp/Rp-CMP-Coumarin
Sp-CMP-coumarin was obtained by digestion of racemic CMP-coumarin with
variant 3B3 that is Rp-CMP-coumarin specific (Ashani et al., 2010), followed by
organic extraction of the intact. Sp-CMP-coumarin. Rp-CMP-coumarin was
obtained in a similar manner using variant VIID2 that is Sp-CMP-coumarin
specific. Purified variants (0.01–0.6 mM) were mixed with either Sp or Rp-
CMP-coumarin (5-1000 mM) in activity buffer in 96-well enzyme-linked immu-
nosorbent assay plates (200 ml per reaction). Product formation wasmonitored
for 5 min at 405 nm and initial velocities were derived. Values of at least three
independent repeats were averaged for determining the kinetic parameters of
each variant by fitting the data directly to a Michaelis-Menten equation usingChemistry & Biology 19,KaleidaGraph. Substrate concentrations were verified by monitoring their
complete hydrolysis using NaF (100 mM).
Kinetic Assay with PMP-Coumarin
Purified variants (0.5 mM)were mixed with racemic PMP-coumarin (10 mM) and
activity buffer as above. The rate of PMP-coumarin hydrolysis was monitored
by measuring the absorbance of released coumarin at 405 nm for up to
200 min. Alternatively, purified Rp-specific variant 3B3 (Ashani et al., 2010;
0.5 mM) was mixed with racemic PMP-coumarin (10 mM) and activity buffer
and product release was monitored for 50 min. Then, the evolved variants
were added (0.5 mM) and product release was monitored for additional
150 min.
Kinetics of GA Hydrolysis by 31P NMR
GA was synthesized at a small (mg) scale without distillation using a modified
protocol (1951, Acta Physiol. Scand. Suppl. 90, 25) and purified of a silica
gel column. A Varian 300 MHz was used to monitor the changes in the 31P
NMR signal of reaction mixtures of GA with PON1 variants. In an NMR
tube, 0.15 ml D2O were added to 0.3 ml reactivity buffer containing 1 mg
O,O-diisopropyl methylphosphonate and the solution was spiked with 50 ml
of a GA stock solution in aceton to provide a final concentration of 1 mg/ml.
After recording the baseline spectrum, the reaction was initiated by the
addition of the corresponding PON1 variant. Twenty pulses were collected
for each scan, data acquisition was repeated every 2-3 min.
Ex Vivo Assays
Protection of ChE’s in human whole blood samples was measured as
described (Ashani et al., 2011). Briefly, purified PON1 variants (0.3–2.5 mM)
were added to pre-heated (37C) human whole blood samples (obtained
from the Israeli blood bank), spiked with CaCl2 (to 2 mM) and adjusted to pH
7.4 with Tris base (1 M). At selected time intervals, in situ prepared GF was
added (0.1 mM) and the residual activity of blood ChEs was assayed as
described (Ashani et al., 2011). The ChE activity was compared to the residual
ChEs activity obtained after 5min incubation in blood. The hydrolytic activity of
PON1 variants (0.3–2.5 mM) following incubation in whole blood (pH 7.4, CaCl2
2mM) was evaluated by dilution of PON1 containing blood samples (1,000-
fold) at different time intervals into activity buffer, addition of racemic CMP-
coumarin (0.3mM), andmeasurement of the rate of hydrolysis as above. These
rates were compared to the rates obtained after 5 min incubation.
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